All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Global turmoil increases case for EU-UK alignment on medicines security

Mark Samuels outlines his argument for greater UK-EU cooperation to ensure that access to medicines across Europe are as shielded as possible... The post Global turmoil increases case for EU-UK…

Read the full article
Joel Reland2mo agoen

You might also wanna read

Five EU countries seek unified response to US and pharma pressure on drug pricing

The U.S. and pharma companies are increasing the pressure on EU countries to pay more for medicines.

politico.eu·1mo ago

UK medicines investment: the case for improving the UK commercial environment

David Watson builds on The King's Fund's explainer on medicines pricing to make the case for policymakers to protect the UK’s position in li

ABPI·12d ago

Brexit denies UK children access to life-extending drug for aggressive brain cancer

Exclusive: Experts say Brexit has led to delays in the launch of clinical trials and increased costs for multiple drugs. They are urging the

The Independent·3d ago

Brexit denies UK children access to life-extending drug for aggressive brain cancer

Exclusive: Experts say Brexit has led to delays in the launch of clinical trials and increased costs for multiple drugs. They are urging the

independent.co.uk·3d ago

David Greene comments on EU-AstraZeneca dispute

AstraZeneca appears to be in danger of breaching its contract to supply the EU, and may have to renegotiate its contract to supply Covid-19

Edwin Coe·5y ago

Analysis: UK-US pharmaceuticals trade deal could divert NHS funds and harm public health

Samuel Cross, Karl Claxton, and Andrew Hill argue that diversion of billions of NHS funding to pay more for new drugs under the UK-US trade

bmj.com·12d ago

Analysis: UK-US pharmaceuticals trade deal could divert NHS funds and harm public health

Samuel Cross, Karl Claxton, and Andrew Hill argue that diversion of billions of NHS funding to pay more for new drugs under the UK-US trade

bmj.com·12d ago

Starmer's US pharma deal criticized as costly threat to NHS and public health

The deal on medicine imports will cost the NHS billions and take funding away from doctors, nurses, cancer scans and the rest, says Guardian

theguardian.com·13d ago

Comments

Sign in to join the conversation.

No comments yet. Be the first.